Invex Therapeutics Ltd. (AU:IXC) has released an update.
Invex Therapeutics Ltd has concluded its Phase III IIH EVOLVE clinical trial and is now focusing on the development and commercialization of Exenatide for treating neurological conditions linked to increased intracranial pressure. The company reported successful completion of the trial, finalization of associated administrative tasks, and a recent publication highlighting Exenatide’s lack of negative impact on cognition in patients. Invex continues to evaluate opportunities to augment its portfolio in the neurological field and holds a strong cash position with no current binding commitments for new technologies.
For further insights into AU:IXC stock, check out TipRanks’ Stock Analysis page.
